CCR9 inhibitors and methods of use thereof

US7999109B2 · kind B2 · utility

Assignee

• Millennium Pharmaceuticals, Inc. · US

Inventors

• Paul E. Fleming · Wellesley, US
• Geraldine C. Harriman · Charlestown, US
• Zhan Shi · Concord, US
• B. Shaowu Chen · Sudbury, US

Key dates

• Filing date: Dec 17, 2009
• Grant date: Aug 16, 2011
• Expiry date: Dec 17, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.